CStone plans first wave of global Phase III trials for CS2009 by end-2026PUBT·1 day ago, 12:23 PM02616-0.78%
CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial MomentumPR Newswire·1 day ago, 12:22 PM02616-0.78%
CStone Pharmaceuticals: Revenue up 315% YoY, losses narrowed, and major clinical and commercial milestones achievedQuartr·Aug 27 at 11:39 AM02616-0.78%
CStone 1H FY26 loss narrows to RMB 252.28 million; revenue rises to RMB 205.1 millionPUBT·Aug 27 at 11:32 AM02616-0.78%
CStone says China NMPA clears IND for CS5007 EGFR/HER3 bispecific ADCPUBT·Aug 20 at 10:02 PM02616-0.78%
CStone Management Boosts Shareholdings as Key Immuno-Oncology Asset AdvancesTip Ranks·Jul 22 at 10:37 PM02616-0.78%
CStone’s Trispecific Cancer Antibody CS2009 Secures Dual Rapid Oral Slots at ESMO 2026Tip Ranks·Jul 20 at 12:07 AM02616-0.78%
CStone signs exclusive sugemalimab commercialization deal with Arrotex for Australia, New ZealandPUBT·Jun 25 at 09:01 AM02616-0.78%
CStone files HKEX next-day disclosure return on share repurchase for cancellationPUBT·Jun 24 at 02:30 PM02616-0.78%
CStone Shareholders Approve All AGM Resolutions, Renew Capital Mandates and CEO Equity AwardsTip Ranks·Jun 23 at 11:13 PM02616-0.78%
CStone Pharmaceuticals files HKEX next-day disclosure, reports share repurchase for cancellationPUBT·Jun 22 at 11:39 AM02616-0.78%
CStone files HKEX next-day return disclosing share repurchase for cancellation at HKD 4.53-4.83PUBT·Jun 17 at 10:33 AM02616-0.78%
